Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘We Need More Time‘: Medtech Groups Testify Before EPA On ETO Emissions Regulation

Executive Summary

Medtech groups call for extended commentary and compliance periods for two new EtO regulations from the EPA. 

You may also be interested in...



CDRH On Track To Meet All MDUFA V Goals

CDRH is on track to meet its MDUFA V goals, seeing a steady return to pre-pandemic levels of device authorizations and submissions.

Harmonizing EPA And Industry Needs: EtO Emissions

The EPA and medtech industry want the same things: Cleaner air and a steady supply of medical devices. So how do they reconcile their differences?

EPA Gives Stakeholders Additional 15 Days For EtO Comments

The deadline for comments on the Environmental Protection Agency proposal, which trade groups say could lead to device shortages if implemented, has been moved from 12 June to 27 June. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147909

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel